Hepatitis B treatment, Baraclude’s drug price cut from the 7th

From the 7^th, the upper health insurance benefit of the BMS Pharmaceutical Korea’s(CEO Hye-sun Park) chronic hepatitis B treatment, Baraclude(generic name: entecavir), will be lowered to 53.55% of the original price before the patent expiration.

The drug price cut is followed by the Ministry of Health and Welfare’s(MOHW) patent-expired drug price reduction policy; the Baraclude’s drug price ha...